Cargando…
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
Histone lysine acetylation is critical in regulating transcription. Dysregulation of this process results in aberrant gene expression in various diseases, including cancer. The bromodomain, present in several proteins, recognizes promotor lysine acetylation and recruits other transcription factors....
Autores principales: | Alqahtani, Ali, Choucair, Khalil, Ashraf, Mushtaq, Hammouda, Danae M, Alloghbi, Abduraham, Khan, Talal, Senzer, Neil, Nemunaitis, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426170/ https://www.ncbi.nlm.nih.gov/pubmed/30906568 http://dx.doi.org/10.4155/fsoa-2018-0115 |
Ejemplares similares
-
Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
por: Alqahtani, Ali, et al.
Publicado: (2019) -
Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020) -
77232 The role of the bromodomain and extra-terminal motif (BET) family of proteins in head and neck cancer tumorigenic phenotype
por: Sample, Reilly A., et al.
Publicado: (2021) -
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020) -
Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)